Clinical Trial

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated January 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-04.
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT05489289
Lead Sponsor Akeso
Conditions Hepatocellular Carcinoma
Enrollment 570 participants
Start Date 2023-01-05
Primary Completion 2026-01-28 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-12